AR099989A1 - Proceso de preparación de (s)-1-(1-(4-cloro-3-fluorofenil)-2-hidroxietil)-4-(2-((1-metil-1h-pirazol-5-il)amino)pirimidin-4-il)-2(1h)-ona y sus sales - Google Patents
Proceso de preparación de (s)-1-(1-(4-cloro-3-fluorofenil)-2-hidroxietil)-4-(2-((1-metil-1h-pirazol-5-il)amino)pirimidin-4-il)-2(1h)-ona y sus salesInfo
- Publication number
- AR099989A1 AR099989A1 ARP150101063A ARP150101063A AR099989A1 AR 099989 A1 AR099989 A1 AR 099989A1 AR P150101063 A ARP150101063 A AR P150101063A AR P150101063 A ARP150101063 A AR P150101063A AR 099989 A1 AR099989 A1 AR 099989A1
- Authority
- AR
- Argentina
- Prior art keywords
- formula
- compound
- approximately
- chloro
- contacting
- Prior art date
Links
- -1 1- (4-CHLORO-3-FLUOROPHENYL) -2-HYDROXYETHYL Chemical class 0.000 title abstract 3
- 238000002360 preparation method Methods 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000003960 organic solvent Substances 0.000 abstract 2
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 2
- ZNGGAPYUQROFJC-QMMMGPOBSA-N (1r)-1-(4-chloro-3-fluorophenyl)ethane-1,2-diol Chemical compound OC[C@H](O)C1=CC=C(Cl)C(F)=C1 ZNGGAPYUQROFJC-QMMMGPOBSA-N 0.000 abstract 1
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 abstract 1
- FRSBDALHVZFPHT-UHFFFAOYSA-N 2-chloro-1-(4-chloro-3-fluorophenyl)ethanone Chemical compound FC1=CC(C(=O)CCl)=CC=C1Cl FRSBDALHVZFPHT-UHFFFAOYSA-N 0.000 abstract 1
- SCOJKGRNQDKFRP-UHFFFAOYSA-N 2-chloro-n-methoxy-n-methylacetamide Chemical compound CON(C)C(=O)CCl SCOJKGRNQDKFRP-UHFFFAOYSA-N 0.000 abstract 1
- JESRNIJXVIFVOV-UHFFFAOYSA-N 2-methylpyrazol-3-amine Chemical compound CN1N=CC=C1N JESRNIJXVIFVOV-UHFFFAOYSA-N 0.000 abstract 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 abstract 1
- AGYWDGVTLKNTBS-UHFFFAOYSA-N 4-bromo-1-chloro-2-fluorobenzene Chemical compound FC1=CC(Br)=CC=C1Cl AGYWDGVTLKNTBS-UHFFFAOYSA-N 0.000 abstract 1
- RAEXTEKKMYSCEX-UHFFFAOYSA-N CS(=O)(=O)C1=NC=CC(=N1)C1=CC(NC=C1)=O Chemical compound CS(=O)(=O)C1=NC=CC(=N1)C1=CC(NC=C1)=O RAEXTEKKMYSCEX-UHFFFAOYSA-N 0.000 abstract 1
- 101001110310 Lentilactobacillus kefiri NADP-dependent (R)-specific alcohol dehydrogenase Proteins 0.000 abstract 1
- 239000004280 Sodium formate Substances 0.000 abstract 1
- 239000000010 aprotic solvent Substances 0.000 abstract 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical class [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 abstract 1
- KOPOQZFJUQMUML-UHFFFAOYSA-N chlorosilane Chemical compound Cl[SiH3] KOPOQZFJUQMUML-UHFFFAOYSA-N 0.000 abstract 1
- 235000019253 formic acid Nutrition 0.000 abstract 1
- 238000006263 metalation reaction Methods 0.000 abstract 1
- 150000002901 organomagnesium compounds Chemical class 0.000 abstract 1
- 239000007800 oxidant agent Substances 0.000 abstract 1
- 239000003880 polar aprotic solvent Substances 0.000 abstract 1
- HLBBKKJFGFRGMU-UHFFFAOYSA-M sodium formate Chemical compound [Na+].[O-]C=O HLBBKKJFGFRGMU-UHFFFAOYSA-M 0.000 abstract 1
- 235000019254 sodium formate Nutrition 0.000 abstract 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
- C12P17/165—Heterorings having nitrogen atoms as the only ring heteroatoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2014075011 | 2014-04-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR099989A1 true AR099989A1 (es) | 2016-08-31 |
Family
ID=54287327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150101063A AR099989A1 (es) | 2014-04-09 | 2015-04-08 | Proceso de preparación de (s)-1-(1-(4-cloro-3-fluorofenil)-2-hidroxietil)-4-(2-((1-metil-1h-pirazol-5-il)amino)pirimidin-4-il)-2(1h)-ona y sus sales |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US20170022183A1 (enExample) |
| EP (2) | EP3494971B1 (enExample) |
| JP (3) | JP6723926B2 (enExample) |
| KR (3) | KR20200038553A (enExample) |
| CN (3) | CN112645927A (enExample) |
| AR (1) | AR099989A1 (enExample) |
| AU (2) | AU2015245743B2 (enExample) |
| BR (2) | BR122020014933B8 (enExample) |
| CA (2) | CA2945098C (enExample) |
| ES (1) | ES2733495T3 (enExample) |
| HR (1) | HRP20191306T1 (enExample) |
| IL (2) | IL248205B (enExample) |
| MX (2) | MX375638B (enExample) |
| MY (3) | MY188526A (enExample) |
| NZ (1) | NZ725450A (enExample) |
| PL (1) | PL3129025T3 (enExample) |
| RU (1) | RU2684102C2 (enExample) |
| SG (1) | SG11201608421XA (enExample) |
| SI (1) | SI3129025T1 (enExample) |
| TW (2) | TWI678366B (enExample) |
| WO (1) | WO2015154674A1 (enExample) |
| ZA (1) | ZA201607066B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT201800282T1 (it) * | 2012-03-01 | 2018-07-17 | Genentech Inc | Inibitori delle serina/treonina chinasi |
| US9532987B2 (en) | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
| UA120506C2 (uk) | 2013-12-06 | 2019-12-26 | Дженентек, Інк. | Інгібітори серин/треонінкіназ |
| EP3494971B1 (en) | 2014-04-09 | 2024-07-24 | Genentech, Inc. | Salts of erk inhibitors |
| CR20180316A (es) | 2015-11-09 | 2018-10-05 | Astrazeneca Ab | Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer |
| KR20180134347A (ko) | 2016-04-15 | 2018-12-18 | 제넨테크, 인크. | 암의 진단 및 치료 방법 |
| JP7530829B2 (ja) | 2017-09-08 | 2024-08-08 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | がんの診断及び治療方法 |
| US20210008047A1 (en) | 2018-02-13 | 2021-01-14 | Vib Vzw | Targeting minimal residual disease in cancer with rxr antagonists |
| EP3546447A1 (en) * | 2018-03-29 | 2019-10-02 | Heidelberg Pharma GmbH | Synthesis of (2s,3r,4r)-4,5-dihydroxyisoleucine and derivatives |
| WO2021110893A1 (en) * | 2019-12-05 | 2021-06-10 | Astrazeneca Ab | Process and intermediates for the production of formula (i) |
| CN115710158A (zh) * | 2021-08-23 | 2023-02-24 | 凯特立斯（深圳）科技有限公司 | 一种不对称催化制备替格瑞洛中间体的方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY130778A (en) * | 2001-02-09 | 2007-07-31 | Vertex Pharma | Heterocyclic inhibitiors of erk2 and uses thereof |
| US6869966B2 (en) * | 2002-09-30 | 2005-03-22 | Banyu Pharmaceutical Co., Ltd. | N-substituted-2-oxodihydropyridine derivatives |
| EP2001849B1 (en) * | 2006-03-29 | 2014-11-26 | F. Hoffmann-La Roche AG | Pyridine and pyrimidine derivatives as mglur2 antagonists |
| JP2011503006A (ja) * | 2007-11-06 | 2011-01-27 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー | 殺菌性複素環アミン |
| SMT201800282T1 (it) * | 2012-03-01 | 2018-07-17 | Genentech Inc | Inibitori delle serina/treonina chinasi |
| US9867667B2 (en) * | 2014-02-27 | 2018-01-16 | Canon Usa Inc. | Placement apparatus |
| EP3494971B1 (en) | 2014-04-09 | 2024-07-24 | Genentech, Inc. | Salts of erk inhibitors |
-
2015
- 2015-04-08 EP EP19152874.4A patent/EP3494971B1/en active Active
- 2015-04-08 WO PCT/CN2015/076083 patent/WO2015154674A1/en not_active Ceased
- 2015-04-08 TW TW104111317A patent/TWI678366B/zh not_active IP Right Cessation
- 2015-04-08 CN CN202011466648.XA patent/CN112645927A/zh active Pending
- 2015-04-08 KR KR1020207009606A patent/KR20200038553A/ko not_active Ceased
- 2015-04-08 SG SG11201608421XA patent/SG11201608421XA/en unknown
- 2015-04-08 KR KR1020227045548A patent/KR20230006043A/ko not_active Abandoned
- 2015-04-08 SI SI201530799T patent/SI3129025T1/sl unknown
- 2015-04-08 RU RU2016139286A patent/RU2684102C2/ru active
- 2015-04-08 MX MX2016013162A patent/MX375638B/es active IP Right Grant
- 2015-04-08 PL PL15776904T patent/PL3129025T3/pl unknown
- 2015-04-08 TW TW108130327A patent/TWI762806B/zh not_active IP Right Cessation
- 2015-04-08 MY MYPI2016001816A patent/MY188526A/en unknown
- 2015-04-08 BR BR122020014933A patent/BR122020014933B8/pt active IP Right Grant
- 2015-04-08 MX MX2020010384A patent/MX392460B/es unknown
- 2015-04-08 ES ES15776904T patent/ES2733495T3/es active Active
- 2015-04-08 MY MYPI2021005416A patent/MY198371A/en unknown
- 2015-04-08 BR BR112016023391-3A patent/BR112016023391B1/pt not_active IP Right Cessation
- 2015-04-08 CN CN201580029835.2A patent/CN106659721B/zh active Active
- 2015-04-08 CA CA2945098A patent/CA2945098C/en active Active
- 2015-04-08 JP JP2016561841A patent/JP6723926B2/ja active Active
- 2015-04-08 HR HRP20191306TT patent/HRP20191306T1/hr unknown
- 2015-04-08 EP EP15776904.3A patent/EP3129025B1/en active Active
- 2015-04-08 CN CN202010547624.0A patent/CN111777594B/zh active Active
- 2015-04-08 AU AU2015245743A patent/AU2015245743B2/en not_active Ceased
- 2015-04-08 AR ARP150101063A patent/AR099989A1/es unknown
- 2015-04-08 MY MYPI2021005412A patent/MY196320A/en unknown
- 2015-04-08 CA CA3167641A patent/CA3167641A1/en active Pending
- 2015-04-08 NZ NZ725450A patent/NZ725450A/en not_active IP Right Cessation
- 2015-04-08 KR KR1020167030901A patent/KR102490955B1/ko active Active
-
2016
- 2016-10-05 US US15/285,781 patent/US20170022183A1/en not_active Abandoned
- 2016-10-06 IL IL248205A patent/IL248205B/en active IP Right Grant
- 2016-10-13 ZA ZA2016/07066A patent/ZA201607066B/en unknown
-
2018
- 2018-01-10 US US15/866,899 patent/US10611753B2/en active Active
-
2019
- 2019-08-08 US US16/535,752 patent/US11098028B2/en active Active
- 2019-08-13 IL IL26869019A patent/IL268690A/en unknown
- 2019-12-18 US US16/718,602 patent/US11066389B2/en active Active
-
2020
- 2020-03-02 JP JP2020035010A patent/JP6974524B2/ja active Active
- 2020-08-21 AU AU2020220208A patent/AU2020220208B2/en not_active Ceased
-
2021
- 2021-06-22 JP JP2021102810A patent/JP2021167321A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR099989A1 (es) | Proceso de preparación de (s)-1-(1-(4-cloro-3-fluorofenil)-2-hidroxietil)-4-(2-((1-metil-1h-pirazol-5-il)amino)pirimidin-4-il)-2(1h)-ona y sus sales | |
| CL2021000611A1 (es) | Proceso para preparar n-(5-(3-(7-(3-fluorofenil)-3h-imidazo[4,5-c]piridin-2-il)-1h-indazol-5-il)piridin-3-il)-3-metilbutanamida por acoplamiento entre un indazol y una pirimidina; ciclación para formar un azabenzimidazol y desprotección del grupo indazol con tfa puro (divisional de la solicitud no. 201803423) | |
| AR105292A1 (es) | Fenoxihalogenofenilamidinas y su uso como fungicidas | |
| AR098108A1 (es) | Proceso para la preparación de 3-(3-cloro-1h-pirazol-1-il)piridina | |
| JP2015063536A5 (enExample) | ||
| WO2013184480A3 (en) | Processes to produce certain 2-(pyridine-3-yl)thiazoles | |
| MX383885B (es) | Compuestos de heteroarilo anulares fusionados y su uso como inhibidores del receptor de la tirosina cinasa (trk). | |
| MX388606B (es) | Sales del inhibidor fosfoinositida 3-cinasa (pi3k) y procesos para su preparacion. | |
| MX379536B (es) | Compuestos de pirimidinio sustituido y derivados para combatir plagas de animales. | |
| AR098107A1 (es) | Proceso para la preparación de 3-(3-cloro-1h-pirazol-1-il)piridina | |
| AR102570A1 (es) | Síntesis de copanlisib, su sal diclorhidrato, intermediarios para su preparación e hidratos de los mismos | |
| PE20110147A1 (es) | Composicion y proceso - 356 | |
| TR201902080T4 (tr) | N-asil-(3-sübstitüe)-(8-sübstitüe)-5,6-dihidro-[1,2,4]triazolo[4,3-a]pirazinlerinin yeni kiral sentezleri. | |
| EA200870586A1 (ru) | 3-(1,3-бензодиоксол-5-ил)-6-(4-циклопропилпиперазин-1-ил)пиридазин, его соли и сольваты и его применение в качестве антагониста н3 рецептора гистамина | |
| CL2017000106A1 (es) | Novedosas pirimidinas 2,5-sustituidas como inhibidores pde4 . | |
| MX362102B (es) | Método para producir 4-[5-(piridin-4-il)-1h-1,2,4-triazol-3-il]pir idina-2-carbonitrilo e intermediario del mismo. | |
| AR095727A1 (es) | Preparación de intermediarios de pirimidina | |
| AR110119A1 (es) | Proceso para la purificación de pirazolpiridazinas | |
| ES2649740T3 (es) | Método simple para la preparación de 5-nitrotetrazolatos usando un sistema de flujo | |
| MY198759A (en) | Modified oligonucleotides for treatment of polycystic kidney disease | |
| JP2017526665A (ja) | 光学活性イソキサゾリン化合物の製造プロセス | |
| AR083755A1 (es) | Formas solidas del acido (s)-2-amino-3-(4-(-2-amino-6-((r)-1-(4-cloro-2-(3-metil-1h-pirazol-1-il)fenil)-2,2,2-trifluoroetoxi)pirimidin-4-il)fenil)propanoico | |
| MX2022001495A (es) | Procesos novedosos para preparar estimuladores de guanilato ciclasa soluble. | |
| MX382762B (es) | Procesos novedosos para preparacion de estimuladores de guanilato ciclasa soluble. | |
| AR100648A1 (es) | Proceso de preparación de azd5363 y compuesto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |